Skip to main content

Schizophrenia

Switching to aripiprazole or ziprasidone could improve weight and other cardiometabolic outcomes in patients with serious mental illness, according to a systematic review and meta-analysis publishes online in Schizophrenia Bulletin.
Clozapine was 4 times more likely than haloperidol to reduce violence in patients with schizophrenia and conduct disorder, a study published in The American Journal of Psychiatry found.
A machine learning algorithm that previously predicted people with schizophrenia with 87% accuracy has now identified healthy first-degree relatives of such patients with the highest self-reported schizotypal personality scores.
Long-acting injectable (LAI) paliperidone palmitate significantly improved outcomes in patients with schizophrenia despite duration of illness, but those with shorter illness duration showed the best improvement, a study found.
In this video, Leslie Citrome, MD, MPH, discusses the use of long-acting injectable antipsychotics in the treatment of schizophrenia and bipolar disorder.
What does in utero malnutrition have to do with schizophrenia? And why is weight gain, a problematic adverse event, also linked with clinical effectiveness of antipsychotic medications?
Why do so many antipsychotic medications induce symptoms, signs, and physiologic changes that are already present to a lesser degree in the disease states that they are intended to treat?
Back to Top